A vaccine administered during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a decrease of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and transferring immunity through the placenta. A significant recent study examining nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly half of all newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the vaccine safeguards vulnerable infants
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects roughly half of all newborns in their first few months of life. The virus can vary from causing mild cold-like symptoms to causing severe chest infections that leave babies struggling to breathe and feed. In the most severe cases, the lung inflammation becomes life-threatening, with small numbers of infants dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of serious RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they attempt to draw enough oxygen in. This is very, very frightening as a parent, frightening for good reason.”
The pregnancy vaccine works by stimulating the mother’s body’s defences to produce protective antibodies, which are then transferred to the developing baby through the placenta. This maternal immunity offers newborns with immediate protection from the point of delivery, precisely when they are highly susceptible to RSV. The new study demonstrates that protection reaches approximately 85% when the vaccine is administered at least four weeks before delivery. Even briefer gaps between vaccination and birth can still provide meaningful protection, with evidence suggesting that a fortnight’s interval is sufficient to shield babies delivered prematurely. Dr Watson recommends pregnant women to receive the vaccine at the recommended time, whilst noting that protection can still occur even if administered later in the third trimester.
- Nearly 85% protection when vaccinated four weeks before birth
- Antibodies from the mother passed through the placenta protect newborns from day one
- Protection achievable with 2-week gap before premature birth
- Vaccination in the third trimester still provides significant infant protection
Persuasive evidence from the latest research
The efficacy of the pregnancy RSV vaccine has been confirmed through a extensive research programme undertaken in England, reviewing data from nearly 300,000 babies born between September 2024 and March 2025. This represents approximately 90 per cent of all births during that six-month period, providing robust and representative data of the vaccine’s practical effectiveness. The study’s results have been validated by the UK Health Security Agency as showing strong protection for newborns during their most vulnerable early months. The breadth of this investigation gives healthcare professionals and parents-to-be with confidence in the vaccine’s demonstrated effectiveness across different groups and contexts.
The results paint a compelling picture of the vaccine’s protective power. More than 4,500 babies were treated in hospital with RSV during the study period, with the vast majority being infants whose mothers had not been given the vaccination. This marked difference emphasises the vaccine’s critical role in reducing the risk of serious illness in newborns. The reduction in hospital admissions exceeding 80 per cent represents a substantial public health milestone, possibly preventing thousands of infants from experiencing the frightening and potentially life-threatening symptoms associated with severe RSV infection. These findings support the importance of the vaccination programme established in the UK in 2024.
Methodology and scope of study
The research analysed birth and hospitalisation records from England over a six-month timeframe, capturing data on approximately 90% of all births during this timeframe. By examining around 300,000 babies born to vaccinated and unvaccinated mothers, researchers were in a position to determine clear comparisons of RSV infection levels and hospitalisations. The large sample size and comprehensive nature of the data gathering ensured that findings were statistically robust and representative of the broader population, rather than individual cases or limited subgroups.
The study specifically recorded hospital admissions for RSV among infants born to mothers who had received the vaccine at differing periods before delivery. This allowed researchers to determine the minimum time required between vaccination and birth for maximum protection, as well as to determine whether protection stayed significant with shorter intervals. The methodology captured practical outcomes rather than controlled laboratory conditions, providing tangible evidence of how the vaccine functions when given across varied healthcare environments and patient circumstances throughout the final three months of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Understanding RSV and the dangers
Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their early months of life, with severity changing substantially from mild cold-like symptoms to serious, potentially fatal chest infections. More than 20,000 babies require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on paediatric wards and neonatal units during busier periods.
The infection produces deep inflammation in the lungs and airways, making it extremely challenging for affected infants to feed and breathe effectively. Parents commonly see their babies struggling visibly, their chests heaving as they attempt to draw adequate oxygen into their damaged lungs. Whilst most infants improve through clinical support, a small but significant group succumb from respiratory syncytial virus complications yearly, making immunisation programmes a vital health service imperative for defending the most vulnerable and youngest members of society.
- RSV causes lung inflammation, leading to severe breathing difficulties in infants
- Half of all newborns acquire the virus during their first few months alive
- Symptoms span from mild colds to life-threatening chest infections needing hospital treatment
- Over 20,000 UK infants need serious hospital treatment for RSV annually
- Few babies die from RSV complications each year in the UK
Take-up rates and expert recommendations
Since the RSV vaccine programme commenced in 2024, health officials have stressed the importance of pregnant women getting their jab at the optimal time for peak protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has stressed that timing matters greatly for ensuring newborns receive the maximum immunity from birth. Whilst the study demonstrates that vaccination performed at least four weeks prior to delivery provides nearly 85% protection, experts advise women to get their vaccine as soon as feasible from 28 weeks of pregnancy forward to maximise the antibodies transferred to their babies through the placenta.
The messaging from health authorities stays clear: pregnant women should make a priority of getting vaccinated during their final three months, even if circumstances mean they cannot receive the jab at the ideal window. Dr Watson has reassured expectant mothers that protection is still achievable with shorter intervals between immunisation and delivery, including even a fourteen-day window for those delivering slightly early. This adaptable strategy recognises the realities of pregnancy and childbirth whilst maintaining strong protection for at-risk infants during their earliest and most vulnerable period when RSV poses the greatest risk of serious illness.
Regional differences in immunisation
Whilst the RSV vaccine programme has been implemented across England, uptake rates and deployment schedules have differed across different regions and NHS trusts. Some areas have achieved higher vaccination coverage among qualifying expectant mothers, whilst others continue working to increase awareness and access to the jab. These geographical variations demonstrate differences across healthcare infrastructure, engagement approaches, and local engagement efforts, though the overall statistics shows robust and reliable protection regardless of geographical location.
- NHS trusts launching multiple messaging strategies to reach women during pregnancy
- Inconsistencies across regions in vaccination coverage levels in different parts of England demand focused enhancement
- Community health services adapting programmes to align with local requirements and situations
Practical implications and parent viewpoints
The vaccine’s remarkable effectiveness translates into real advantages for families throughout the United Kingdom. With over 20,000 babies admitted to hospital annually due to RSV prior to the launch of this safeguarding intervention, the 80% drop in admissions represents thousands of infants shielded from serious illness. Parents no more face the upsetting situation of seeing their babies labour to breathe or difficulty feeding, symptoms that characterise severe RSV infections. The vaccine has substantially transformed the terrain of neonatal lung health, offering expectant mothers a proactive tool to shield their most vulnerable children during those critical early months.
For families like that of Malachi, whose serious RSV infection led to devastating brain damage, the vaccine’s accessibility carries deep personal significance. His mother’s promotion of the jab highlights the profound consequences that vaccine-preventable disease can cause to young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story resonates powerfully with parents now given protection. The knowledge that such grave complications—hospital stay, oxygen dependency, neurological damage—are now largely avoidable has given considerable reassurance to expectant mothers during their late pregnancy, transforming what was once an unavoidable seasonal threat into a controllable health concern.